undamentalytics Newsletter
Sign in

Charles River Laboratories balance sheet

At the end of fiscal 2025, Charles River Laboratories had total assets of $7.14bn, total liabilities of $3.92bn and shareholders' equity of $3.16bn. It held $214m in cash against $2.14bn of debt: net debt of $1.93bn.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents18317969110156160118118164195238228241234277195214192
Receivables190193185203221258270364430472514618643752780721709712
Inventory103100938889899496115128161186199256380279299346
Total current assets5965534264855535795596578278981,0211,2011,2741,4391,6091,4031,4471,529
Goodwill508198198192313214397888051,2471,5411,8092,7122,8503,0952,8472,7643,077
Total assets2,2041,7331,5581,5861,6331,8712,0682,7122,9303,8564,6935,4917,0247,6038,1957,5287,1357,532
Accounts payable31313431323437687866111122198206169140149141
Deferred revenue (current)71675756547881128118145172208220264242248210203
Total current liabilities2502602173422472953124304645587108401,0331,0921,0559941,1201,135
Short-term debt—31151392132152529283647013005
Long-term debt4576707035276427228211,1881,0921,6101,8501,9302,6642,7082,6472,2402,1362,620
Total debt4937017396736647728631,2351,1451,6681,8881,9802,6662,7112,6532,2432,1402,627
Total liabilities8301,0451,0319839681,1661,3031,8581,8662,5183,0263,3474,4324,5794,5364,0203,9244,644
Shareholders' equity1,3756875266016416727338371,0451,3171,6352,1152,5352,9763,5973,4623,1652,840
Net debt (negative = net cash)3105226715635086127451,1179811,4731,6501,7512,4252,4772,3762,0491,9262,435
Shares outstanding66m56m49m49m48m47m47m47m47m48m49m50m50m51m51m51m49m48m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CRL vs MTDCRL vs ILMNBRKR vs CRLCRL vs WAT

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Charles River Laboratories's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Charles River Laboratories.